Abstract
Introduction
Periodontal diseases are prevalent diseases and are substantial public health burden worldwide. They involve the chronic and progressive destruction of the tooth supporting tissues, mainly the alveolar bone and periodontal ligament (PDL) . These diseases often lead to tooth loss. A major discovery was the finding that periodontal tissue regeneration could be achieved by application of acidic extract of enamel matrix proteins (EMPs) [1, 2] , and later -by the FDA approved medical device termed Emdogain. Emdogain R is an acidic extract of extracellular enamel matrix, and includes a heterogeneous mixture of mainly hydrophobic polypeptides encoded by several genes [1, 3] . It was not clear, however, which of the EMPs induce the regeneration, and what molecular mechanisms are involved [3] . [4] and play a major role in the biomineralization and structural organization of enamel [5, 6] . Amelogenins are hydrophobic molecules that self-assemble in vitro and in vivo into nanospheric structures which regulate the oriented and elongated growth, shape and size of the enamel mineral crystal [7, 8] . During enamel development and mineralization, the abundant secreted amelogenins in the extracellular enamel are sequentially and discretely degraded by specific proteases, the metalloprotease, enamelysin and the serine protease, EMSP-1 (KLK-4) [9] . Other enamel extracellular matrix proteins include: ameloblastin, enamelin (ENAM), tuftelin, dentin phosphoprotein (DPP) and amelotin; these proteins have been implicated in various steps of enamel formation [10] [11] [12] .
Enamel, is an ectodermal tissue covering vertebrate teeth. Mature enamel is composed of highly organized tightly packed hydroxy-apatite crystallites. The major enamel proteins produced during enamel development by the ameloblast cells (a specialized cell layer of the enamel organ) are the amelogenins. They comprise 90% of the developing extracellular EMPs
The EMPs undergo post-translational modifications and postsecretory processing [13] [14] [15] [16] . These factors, as well as alternative mRNA splicing, give rise to the heterogeneous mixture of polypeptides in the enamel matrix. The amelogenins are eventually, together with other EMPs, replaced by mineral ions, calcium and phosphorus, the enamel finally becoming hard, fully mineralized (96%) and mature [17] .
The amelogenin gene contains 7 exons, which undergo alternative mRNA splicing. The most abundant isoform of the native protein secreted into the enamel matrix lacks the internal region encoded by exon 4 . In rodents, a rare isoform including two additional exons termed exons 8 and 9 and lacking exon 7 was reported [18, 19] . Mutations in the X-chromosomal copy of the amelogenin gene [20] [21] [22] [23] . Abnormal enamel formation and mineralization have also been demonstrated by knockout (KO) of amelogenin expression. The teeth of the amelogenin KO mice expressed a hypoplastic enamel phenotype with reduced enamel thickness [24] .
have been associated with the hereditary disease, amelogenesis imperfecta (AI), which illustrates the importance of amelogenin in developing enamel. To date, 15 mutations in AMELX, leading to different phenotypes of AI, have been identified. Mutations in other genes encoding for EMPs, such as ENAM, enamelysin (MMP-20) and kallikrein 4 (KLK-4), were also identified in AI patients
For decades, amelogenin was thought to be exclusively an enamel (epithelial origin) protein. However, in more recent years, amelogenin has also been detected in dentin matrix [2, 25] and odontoblasts [26] , during cementogenesis in remnants of Hertwig's root sheath and in PDL cells [27, 28] . Very [33, 34] , and when implanted in the pulp [35] . In embryonic stem cell cultures, [A-4] was also shown to induce significant increase in bone sialoprotein and osterix gene expression and further mineral matrix formation [36] . Viswanathan et al. demonstrated that the full length recombinant murine amelogenin regulates bonesialoprotein expression in a cementoblast cell line in a dosedependent manner [37] . Tyrosine-rich amelogenin peptide, a specific proteolytic cleavage product of amelogenin, was shown to regulate osteocalcin and osteopontin expression in the same cell line [38] .
A progressive deterioration of cementum (a mineralized tissue covering the tooth root surface) was later observed in the amelogenin KO mice. The defects in cementum were characterized by the increased presence of osteoclasts. These defects were also associated with an increased expression of receptor activator of nuclear factor-B ligand (RANKL) near the cementum, suggesting that amelogenin may play a key role in osteoclastogenesis through the RANKL/RANK mediated pathway [39, 40] . 
Micro-CT analysis

Preparation of rat tissues
Preparation of human mandibular sections
Paraffin embedded sections of human fetal mandibles were prepared by K.H. The Institutional Review Board of the Department of Obstetrics
and Gynecology, University of Helsinki, Finland, had approved the study [42] . 
Indirect immunohistochemistry
In situ hybridization
Production of anti-sense and sense (control) RNA-probes: male Sabra rat incisor enamel organ was carefully dissected using microsurgery tools under a stereo-dissecting microscope [29] (Figs 1 and 2) . Figure 1A presents (Fig. 1B) . In  Fig. 1C, cross (Fig. 1D) and progressive (Fig. 1C) Histological analysis revealed regeneration of all three periodontal tissues; cementum, PDL and alveolar bone in the experimental tooth Histological studies (Fig. 2) (Fig. 2B) , only regenerating cementum, covering the dentin surface, was observed. A region slightly beneath the youngest regenerating tissues (Fig. 2C, upper part -C1 ) contained regenerated cementum and PDL, but no apparent regenerating bone could yet be observed. In older regenerating periodontal tissues (Fig. 2C, (Fig. 3.1-3 (Fig.  3.1A) , in osteoclasts (Fig. 3.1C ) and in few distinct bone marrow cells (Fig. 3.1E) . As was previously reported, amelogenin expression was also detected in PDL cells and in clusters of cementoblasts along the root (Fig. 3.1G) [27, 28] . No staining was detected in the corresponding controls (Fig. 3.1B, D, F and H) . Different staining methods were used, yielding red (Fig. 3.1C and E) to brown (Fig. 3.1A and G (Fig. 3.2A and C) , while no staining was detected in the corresponding control (Fig. 3.2B and D) . In human embryonic mandibular tissue (Fig. 3.3) , amelogenin expression in the epithelial pre-ameloblast cells (Fig. 3.3B ) was much higher than that in the alveolar bone cells (Fig. 3.3A) . No staining was detected in the corresponding controls (Fig. 3.3D and  C) , respectively. [24] were used (Fig. 3.4) . No reaction was detected with the KO mouse enamel organ (Fig. 3.4B ) and periodontal tissues (Fig. 3.4D) , from the same section, but very strong reaction was detected in the corresponding 
Surprisingly, endogenous expression of amelogenin protein was detected in normal (untreated) rat, dog and human periodontal tissues; cementum, PDL and alveolar bone and also in bone marrow
.4). Amelogenin protein was expressed in different types of rat connective tissue cells and in specific bone marrow cells; in rat alveolar bone osteocytes, in osteoblasts lining the alveolar bone trabecules, in cells surrounding blood vessels
) reactions. In normal dog periodontal tissues, staining was detected in PDL cells, in cementoblasts, in osteocytes and in osteoblasts
The amelogenin antibodies generally identified the same cell types. To further determine the specificity of the amelogenin antibodies which reacted with the periodontal tissues, mouse mandibular sections, including the enamel organ and periodontal tissues, from wild-type (WT) and amelogenin KO mouse
. (B) Higher magnification (bar ϭ 20 m) of the regenerating front showing the penetrating oral epithelium (PE) from above and the ascending regenerating cementum from below. Organized PDL and bone are not apparent yet. (C) Enlargement of the regenerated area (bar ϭ 100 m) showing newly regenerated cementum, PDL and bone (lower part -C2). In the younger regenerating area (upper part -C1), only organized regenerating cementum and PDL are apparent.
WT enamel organ (Fig. 3.4A ), and to a lesser extent with the periodontal tissues (Fig. 3.4C ) from the same section, respectively. Amelogenin mRNA (Fig. 4A-F (Fig. 4A and E, respectively) . The same expression pattern was observed for the amelogenin protein ( Fig. 4G and K, (Fig. 5A) , and to a much lesser extent in bone cells distal to the regenerating area (Fig. 5B) . No staining was detected in the control (Fig. 5C) .
) and protein (Fig. 4G-L) expression in rat periodontal tissues was studied. Amelogenin mRNA expression was highest in the alveolar bone adjacent to the PDL, as compared to bone cells distal to the PDL, in the same section
respectively). Higher amelogenin mRNA expression in the periosteal cells was observed, compared to amelogenin expression in bone cells distal to the periosteum (Fig. 4C and E, respectively). Higher amelogenin protein expression was also observed in the periosteum, as compared to bone cells distal to the periosteum (Fig. 4I and K, respectively). No staining was detected in the mRNA and protein corresponding controls, respectively. In the regenerating dog bone, amelogenin was highly expressed in bone endosteal cells, osteoblasts and cells surrounding blood vessels
The number of CD105 and STRO-1 positive cells, both known markers of bone marrow stromal stem cells [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] (Fig. 6.1 and 6.2) . Significantly more CD105 (Fig. 6.1 ) and STRO-1 (Fig. 6.2 20 m, B ϭ bone) . [39] . A progressive deterioration of tooth cementum was observed in the amelogenin KO mice. The defect in cementum was characterized by increased presence of osteoclasts, and was also associated with an increased expression of RANKL in the region of the cementum [39, 40, 56] . Our findings of amelogenin expression in osteoclasts, osteoblasts and bone marrow stromal cells [29] , and the increase in osteoclast activity in the amelogenin KO mice, suggest that amelogenin might function in the fine balance between bone formation by the osteoblasts and bone resorption by the osteoclasts, possibly through the RANKL/RANK mediated pathway [39, 40] . During alveolar bone regeneration after induced inflammation, amelogenin might act by increasing bone formation over the resorption process.
detected in bone cells adjacent to the PDL (A) and in periosteal cells (C) compared to bone cells distal to the PDL and periosteum (E). Parts (B), (D) and (F) are the corresponding sense probe (controls). (G-L) Immunohistochemistry analysis using the amelogenin polyclonal rabbit antibody (270), raised against amelogenin N-terminus, diluted in PBS to 1/500. Similar to the in situ hybridization results, a much higher amelogenin protein expression was detected in bone cells adjacent to the PDL (G) and in periosteal cells (I) as compared with bone cells distal to the PDL and periosteum (K) (in the same slide). Parts (H), (J) and (L) are the corresponding controls, PBS replacing the first antibody (bar ϭ
cells. The large difference in amelogenin expression could explain why the presence of amelogenin protein in bone cells was overlooked in the past. This difference in expression level most probably also represent different role(s) for amelogenin in these tis
The regeneration process requires recruitment and differentiation of a variety of cells. Several studies indicated that amelogenin might be involved in cell signalling. Indeed a cell receptor for LRAP [A-4] , which was previously suggested to have signalling activity (see 'Introduction'), was identified as LAMP-1 [57] . In addition, the full length amelogenin lacking exon 4 (M180), which corresponds to rHAM ϩ [41] , that we used in the present regeneration study, and the short isoform LRAP, were found to bind to LAMP-1, as well as LAMP-2 and CD63 [58] . The exact binding regions of these three proteins for specific amelogenin (M180 and LRAP) sequences were reported [58] . These are ubiquitously expressed lysosomal integral membrane proteins which are also localized to the plasma membrane. Shapiro et al. found that exogenously added amelogenin moves rapidly into established LAMP-1 positive vesicles that subsequently localize to the perinuclear region of the cell [59] . These results [55] . Previously, using immunohistochemistry and confocal microscopy, we reported that some of the long bone marrow CD105 positive cells also express amelogenin [29] . Sequencing of mRNA from dog and rat long bone marrow revealed the expression of full length amelogenin lacking exon 4 and of LRAP (equivalent to mouse M180 and M59, respectively) [29] .
CD105 expression in the (A) granulation tissue, (D) PDL, (G) alveolar bone (B) and bone marrow (BM) of the experimental tooth. CD105 expression in the (B) granulation tissue, (E) PDL, (H) alveolar bone (B) and bone marrow (BM) of the control tooth Statistical analysis comparing the average number of cells expressing CD105 in the (C) granulation tissue, (F) PDL, (I) bone and bone marrow cells of the
In CD105 is also a marker for neovascularization [47, 60, 61] , and STRO-1 positive cells have the potential to differentiate into myofibroblasts with a vascular smooth muscle phenotype [50, 55] [66] . The finding that amelogenin might promote angiogenesis in the regenerating tissues explains Collett et al. [66] and Yuan et al. [67] in vivo and in vitro findings demonstrating chemotaxis of endothelial cells and induction of blood vessel formation by EMPs. As discussed above, ectopic application of LRAP to rat muscle induced mesenchymal cells in-growth into the implants followed by vascularization [68] .
Our 
